4 in 10 Kids' Asthma Biologics Denied by Insurers
4 in 10 Kids' Asthma Biologics Denied by Insurers
4 in 10 Kids' Asthma Biologics Denied by Insurers
Key points
اہم نکات
मुख्य बातें
- Nearly 4 in 10 insurance requests for children's asthma biologic drugs were denied, and approved families waited over a month on average, a new study found.
- Researchers at a children's hospital looked at 326 prescriptions written by allergists for children with severe asthma, eczema, hives or food allergies between 2018 and 2026; the children averaged about 11 years old.
- More than 9 in 10 prescriptions needed prior approval from insurers first, and 39.3% were ultimately denied, mostly because the child did not meet the insurer's coverage rules or had to try another drug first.
- Nearly 4 in 10 insurance requests for children's asthma biologic drugs were denied, and approved families waited over a month on average, a new study found.
- Researchers at a children's hospital looked at 326 prescriptions written by allergists for children with severe asthma, eczema, hives or food allergies between 2018 and 2026; the children averaged about 11 years old.
- More than 9 in 10 prescriptions needed prior approval from insurers first, and 39.3% were ultimately denied, mostly because the child did not meet the insurer's coverage rules or had to try another drug first.
- Nearly 4 in 10 insurance requests for children's asthma biologic drugs were denied, and approved families waited over a month on average, a new study found.
- Researchers at a children's hospital looked at 326 prescriptions written by allergists for children with severe asthma, eczema, hives or food allergies between 2018 and 2026; the children averaged about 11 years old.
- More than 9 in 10 prescriptions needed prior approval from insurers first, and 39.3% were ultimately denied, mostly because the child did not meet the insurer's coverage rules or had to try another drug first.
Nearly 4 in 10 insurance requests for children's asthma biologic drugs were denied, and approved families waited over a month on average, a new study found. Researchers at a children's hospital looked at 326 prescriptions written by allergists for children with severe asthma, eczema, hives or food allergies between 2018 and 2026; the children averaged about 11 years old. More than 9 in 10 prescriptions needed prior approval from insurers first, and 39.3% were ultimately denied, mostly because the child did not meet the insurer's coverage rules or had to try another drug first. The study, presented at the American College of Allergy, Asthma and Immunology's annual meeting, warned that such delays can put children at risk of serious health problems, and its authors called for simpler, faster approval rules.
Nearly 4 in 10 insurance requests for children's asthma biologic drugs were denied, and approved families waited over a month on average, a new study found. Researchers at a children's hospital looked at 326 prescriptions written by allergists for children with severe asthma, eczema, hives or food allergies between 2018 and 2026; the children averaged about 11 years old. More than 9 in 10 prescriptions needed prior approval from insurers first, and 39.3% were ultimately denied, mostly because the child did not meet the insurer's coverage rules or had to try another drug first. The study, presented at the American College of Allergy, Asthma and Immunology's annual meeting, warned that such delays can put children at risk of serious health problems, and its authors called for simpler, faster approval rules.
Nearly 4 in 10 insurance requests for children's asthma biologic drugs were denied, and approved families waited over a month on average, a new study found. Researchers at a children's hospital looked at 326 prescriptions written by allergists for children with severe asthma, eczema, hives or food allergies between 2018 and 2026; the children averaged about 11 years old. More than 9 in 10 prescriptions needed prior approval from insurers first, and 39.3% were ultimately denied, mostly because the child did not meet the insurer's coverage rules or had to try another drug first. The study, presented at the American College of Allergy, Asthma and Immunology's annual meeting, warned that such delays can put children at risk of serious health problems, and its authors called for simpler, faster approval rules.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।